126 related articles for article (PubMed ID: 35144131)
1. Targeted delivery of cancer drug paclitaxel to chordomas tumor cells via an RNA nanoparticle harboring an EGFR aptamer.
Xiao D; Huang Y; Huang S; Zhuang J; Chen P; Wang Y; Zhang L
Colloids Surf B Biointerfaces; 2022 Apr; 212():112366. PubMed ID: 35144131
[TBL] [Abstract][Full Text] [Related]
2. Self-assembled RNA nanocarrier-mediated chemotherapy combined with molecular targeting in the treatment of esophageal squamous cell carcinoma.
Li X; Zhang L; Guo X; Xie F; Shen C; Jun Y; Luo C; Liu L; Yu X; Zhang Z; Wang Q; Gao Y; Xu K
J Nanobiotechnology; 2021 Nov; 19(1):388. PubMed ID: 34823537
[TBL] [Abstract][Full Text] [Related]
3. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.
Pi F; Zhang H; Li H; Thiviyanathan V; Gorenstein DG; Sood AK; Guo P
Nanomedicine; 2017 Apr; 13(3):1183-1193. PubMed ID: 27890659
[TBL] [Abstract][Full Text] [Related]
4. HPA aptamer functionalized paclitaxel-loaded PLGA nanoparticles for enhanced anticancer therapy through targeted effects and microenvironment modulation.
Duan T; Xu Z; Sun F; Wang Y; Zhang J; Luo C; Wang M
Biomed Pharmacother; 2019 Sep; 117():109121. PubMed ID: 31252265
[TBL] [Abstract][Full Text] [Related]
5. Targeting oncogenic
Yang L; Li Z; Binzel DW; Guo P; Williams TM
Mol Ther Nucleic Acids; 2023 Sep; 33():559-571. PubMed ID: 37637206
[No Abstract] [Full Text] [Related]
6. Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis.
Kang SJ; Jeong HY; Kim MW; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Park YS
Nanoscale; 2018 Nov; 10(41):19338-19350. PubMed ID: 30307008
[TBL] [Abstract][Full Text] [Related]
7. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
Yu C; Hu Y; Duan J; Yuan W; Wang C; Xu H; Yang XD
PLoS One; 2011; 6(9):e24077. PubMed ID: 21912664
[TBL] [Abstract][Full Text] [Related]
8. Ultra-thermostable RNA nanoparticles for solubilizing and high-yield loading of paclitaxel for breast cancer therapy.
Guo S; Vieweger M; Zhang K; Yin H; Wang H; Li X; Li S; Hu S; Sparreboom A; Evers BM; Dong Y; Chiu W; Guo P
Nat Commun; 2020 Feb; 11(1):972. PubMed ID: 32080195
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.
Zhang C; Zhao Y; Zhang E; Jiang M; Zhi D; Chen H; Cui S; Zhen Y; Cui J; Zhang S
Drug Deliv; 2020 Dec; 27(1):1397-1411. PubMed ID: 33096948
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
11. Fabrication and evaluation of aptamer-conjugated paclitaxel-loaded magnetic nanoparticles for targeted therapy on breast cancer cells.
Khodadadi E; Mahjoub S; Arabi MS; Najafzadehvarzi H; Nasirian V
Mol Biol Rep; 2021 Mar; 48(3):2105-2116. PubMed ID: 33635469
[TBL] [Abstract][Full Text] [Related]
12. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
13. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance.
Wang H; Ellipilli S; Lee WJ; Li X; Vieweger M; Ho YS; Guo P
J Control Release; 2021 Feb; 330():173-184. PubMed ID: 33316298
[TBL] [Abstract][Full Text] [Related]
14. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Milane L; Duan Z; Amiji M
PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel-Loaded Self-Assembled Lipid Nanoparticles as Targeted Drug Delivery Systems for the Treatment of Aggressive Ovarian Cancer.
Zhai J; Luwor RB; Ahmed N; Escalona R; Tan FH; Fong C; Ratcliffe J; Scoble JA; Drummond CJ; Tran N
ACS Appl Mater Interfaces; 2018 Aug; 10(30):25174-25185. PubMed ID: 29963859
[TBL] [Abstract][Full Text] [Related]
17. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
18. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy.
Garbuzenko OB; Kuzmov A; Taratula O; Pine SR; Minko T
Theranostics; 2019; 9(26):8362-8376. PubMed ID: 31754402
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
20. Utilizing RNA nanotechnology to construct negatively charged and ultrasound-responsive nanodroplets for targeted delivery of siRNA.
Guo L; Shi D; Shang M; Sun X; Meng D; Liu X; Zhou X; Li J
Drug Deliv; 2022 Dec; 29(1):316-327. PubMed ID: 35037525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
